ArticleArchives of dermatological research2024
Factors associated with comorbidity development in atopic dermatitis: a cross-section study.
Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Atopic Dermatitis Beyond the Skin Barrier: Precision Medicine Approaches to Immunological Profiling and Therapeutic Innovation.International journal of molecular sciences · 2026Review
- Letter: factors associated with comorbidity development in atopic dermatitis: a cross-sectional study : Addressing bias and inconsistencies in AntiTNF-induced psoriasis management.Archives of dermatological research · 2025Article
- Critical insights on "Factors associated with comorbidity development in atopic dermatitis: a cross-section study".Archives of dermatological research · 2025Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identifying the characteristics of atopic dermatitis (AD) patients with its comorbidity has become increasingly crucial. We aimed to investigate the relevant factors associated with comorbidities in adults with AD. We analyzed cross-sectional data through univariate and multivariate regression analyses, encompassing 439 adult cases of AD from the Clinical Research and Homogenization Diagnosis and Treatment Project for Type 2 Inflammatory Dermatosis. It was found that 231 patients developed at least one comorbidity. 161 cases had a positive family history of atopy, 292 exhibited elevated IgE levels. A family history of allergic rhinitis or sinusitis was found to be associated with concurrent diseases (OR (95% CI): 2.92 (1.41-6.06) in model 1; 2.71 (1.27-5.77) in model 2; 3.59 (1.75-7.37) in model 3; 3.38 (1.62-7.05) in model 4; 3.60 (1.83-7.08) in model 5; 3.56 (1.78-7.12) in model 6). The linkage between elevated IgE levels and concurrent diseases with different classifications was negative (OR (95% CI): 0.51 (0.33-0.79) in model 1; 0.51 (0.33-0.80) in model 2; 0.51 (0.33-0.79) in model 3; 0.52 (0.33-0.81) in model 4; 0.45 (0.29-0.71) in model 5; 0.47 (0.30-0.73) in model 6). Scores for familial atopy (OR (95% CI): 1.56 (1.00-2.44) in model 2; 1.59 (1.03-2.48) in model 4; 1.84 (1.19-2.84) in model 6) were positively associated with comorbidities. Factors associated with comorbidity development in AD included a family history of allergic rhinitis or sinusitis, elevated IgE levels and scores indicating familial atopy. These relevant factors might contribute to improved discrimination and early intervention for comorbidities in individuals with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.